Drug intelligence / Profile preview

KCB 100

Development stage: Unknown
Lead developer: Kapoose Creek Bio
Modality: Small Molecules

Overview

KCB 100 is a small molecule drug candidate derived from a natural source and developed by Kapoose Creek Bio for the treatment of neurodegenerative diseases. Its precise mechanism of action has not been defined or disclosed publicly. As of the latest updates, it is classified as a new molecular entity and remains in early-stage research and discovery phases for neurodegenerative disorders[3][4].

Beyond the preview

Go deeper on KCB 100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KCB 100.

Explore the full profile